首页> 外文期刊>The Indian journal of tuberculosis >Effect of HIV protease inhibitors and Orlistat on mycobacterial ES-31 serine protease, a potential drug target in Mycobacterium tuberculosis.
【24h】

Effect of HIV protease inhibitors and Orlistat on mycobacterial ES-31 serine protease, a potential drug target in Mycobacterium tuberculosis.

机译:HIV蛋白酶抑制剂和奥利司他对分枝杆菌ES-31丝氨酸蛋白酶(结核分枝杆菌的潜在药物靶标)的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Mycobacterial excretory secretory-31 (SEVA TB ES-31) antigen is shown to possess protease and lipase activities. AIM: To study the effect of commonly used HIV-protease inhibitors and lipase inhibitor Orlistat if any on mycobacterial ES-31 serine protease in vitro enzyme activity and on the growth of M.tb H37Ra bacilli in axenic culture. METHODS: Effect of HIV-protease inhibitors namely Ritonavir, Lopinavir and Indinavir and Orlistat on protease activity of ES-31 was assessed using azocasein assay and on bacillary growth in axenic culture of Mycobacterium tuberculosis H37Ra. The concentration of ES-31 antigen in culture filtrate was determined by sandwich peroxidase ELISA using anti ES-31 antibody and the growth of bacilli by CFU count. RESULTS: HIV-protease inhibitors such as Ritonavir, Lopinavir and Indinavir and lipase inhibitor Orlistat inhibited serine protease activity by 41.3 - 69.7% in vitro. These inhibitors also showed decreased bacterial growth in axenic culture and further confirmed by decreased concentration of ES-31 serine protease secretion in the culture fluid. Ritonavir showed maximum inhibition of 77% on the growth of the bacilli in axenic culture while anti obesity drug Orlistat showed 61% inhibition. CONCLUSION: SEVA TB ES-31 with serine protease and lipase activities may be a potential drug target in tuberculosis management.
机译:背景:分枝杆菌分泌分泌物31(SEVA TB ES-31)抗原显示具有蛋白酶和脂肪酶活性。目的:研究常用的HIV蛋白酶抑制剂和脂肪酶抑制剂奥利司他(如果有的话)对分枝杆菌ES-31丝氨酸蛋白酶体外酶活性和对M.tb H37Ra杆菌生长的影响。方法:使用偶氮酪蛋白测定法评估了利托那韦,洛匹那韦和茚地那韦和奥利司他这两种HIV蛋白酶抑制剂对ES-31蛋白酶活性的影响以及对结核分枝杆菌H37Ra的无性培养中细菌生长的影响。通过使用抗ES-31抗体的夹心过氧化物酶ELISA测定培养滤液中ES-31抗原的浓度,并通过CFU计数确定细菌的生长。结果:利托那韦,洛品那韦和茚地那韦等HIV蛋白酶抑制剂和脂酶抑制剂奥利司他在体外抑制丝氨酸蛋白酶的活性为41.3-69.7%。这些抑制剂还显示出在低密度培养物中细菌生长的减少,并通过培养液中ES-31丝氨酸蛋白酶分泌浓度的降低进一步证实。利托那韦在无菌培养物中显示出对细菌生长的最大抑制作用,为77%,而抗肥胖药Orlistat显示抑制作用为61%。结论:具有丝氨酸蛋白酶和脂肪酶活性的SEVA TB ES-31可能是结核病治疗的潜在药物靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号